Quirine C. van Rossum‐Schornagel
Sint Franciscus Gasthuis(NL)Franciscus Vlietland(NL)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Estrogen and related hormone effects, HER2/EGFR in Cancer Research
Most-Cited Works
- → Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).(2023)89 cited
- → Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer(2024)52 cited
- → Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen(2019)48 cited
- → Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer(2021)29 cited
- → The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer(2023)13 cited
- → CBD-oil as a potential solution in case of severe tamoxifen-related side effects(2023)10 cited
- → A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial(2016)8 cited
- → 191P Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer: The TOTAM study(2020)5 cited
- → Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?(2021)4 cited
- → Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment(2022)4 cited